Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

Safety and Efficacy of TSHA-102 in Pediatric Females with Rett Syndrome (REVEAL Pediatric Study)


NCTID NCT06152237 (View at clinicaltrials.gov)
Description
Development Status Active
Indication Rett Syndrome
Disease Ontology Term DOID:1206
Compound Name TSHA-102
Sponsor Taysha Gene Therapies, Inc.
Funder Type Industry
Recruitment Status
Recruiting
Enrollment Count 20
Results Posted Not Available

Therapy Information


Target Gene/Variant MiniMECP2
Therapy Type Gene transfer
Therapy Route In-vivo
Mechanism of Action Functional gene replacement
Route of Administration Intrathecal
Drug Product Type Viral vector
Target Tissue/Cell
Delivery System Viral transduction
Vector Type scAAV9
Editor Type none
Dose 1 5.7E14 vg (n=4)
Dose 2 1E15 vg (n=6)
Dose 3
Dose 4
Dose 5

Study Record Dates


Current Stage Phase1, Phase2
Submit Date 2023-11-21
Completion Date 2031-11-02
Last Update 2024-11-12

Participation Criteria


Eligible Age 5 Years - 8 Years
Standard Ages Child
Sexes Eligible for Study FEMALE

Locations


No.of Trial Sites 10
Locations Canada,United States,United Kingdom

Regulatory Information


Has US IND True
FDA Designations Fast Track, Orphan Drug Designation, Rare Pediatric Disease Designation, Regenerative Medicine Advanced Therapy
Recent Updates Update on pivotal trial design expected in 1H2025

Resources/Links